Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.

Ji X, Qian J, Rahman SMJ, Siska PJ, Zou Y, Harris BK, Hoeksema MD, Trenary IA, Heidi C, Eisenberg R, Rathmell JC, Young JD, Massion PP.

Oncogene. 2018 Sep;37(36):5007-5019. doi: 10.1038/s41388-018-0307-z. Epub 2018 May 23.

2.

The airway epithelium undergoes metabolic reprogramming in individuals at high risk for lung cancer.

Rahman SMJ, Ji X, Zimmerman LJ, Li M, Harris BK, Hoeksema MD, Trenary IA, Zou Y, Qian J, Slebos RJ, Beane J, Spira A, Shyr Y, Eisenberg R, Liebler DC, Young JD, Massion PP.

JCI Insight. 2016 Nov 17;1(19):e88814. doi: 10.1172/jci.insight.88814.

3.

Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis.

Boutaud O, Sosa IR, Amin T, Oram D, Adler D, Hwang HS, Crews BC, Milne G, Harris BK, Hoeksema M, Knollmann BC, Lammers PE, Marnett LJ, Massion PP, Oates JA.

Cancer Prev Res (Phila). 2016 Nov;9(11):855-865. Epub 2016 Aug 23.

4.

Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.

Hassanein M, Hight MR, Buck JR, Tantawy MN, Nickels ML, Hoeksema MD, Harris BK, Boyd K, Massion PP, Manning HC.

Mol Imaging Biol. 2016 Feb;18(1):18-23. doi: 10.1007/s11307-015-0862-4.

5.

Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.

Hassanein M, Qian J, Hoeksema MD, Wang J, Jacobovitz M, Ji X, Harris FT, Harris BK, Boyd KL, Chen H, Eisenberg R, Massion PP.

Int J Cancer. 2015 Oct 1;137(7):1587-97. doi: 10.1002/ijc.29535. Epub 2015 May 6.

6.

The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers.

Qian J, Hassanein M, Hoeksema MD, Harris BK, Zou Y, Chen H, Lu P, Eisenberg R, Wang J, Espinosa A, Ji X, Harris FT, Rahman SM, Massion PP.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3469-74. doi: 10.1073/pnas.1421975112. Epub 2015 Mar 2.

7.

SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.

Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H, Clark JE, Alborn WE, Eisenberg R, Massion PP.

Clin Cancer Res. 2013 Feb 1;19(3):560-70. doi: 10.1158/1078-0432.CCR-12-2334. Epub 2012 Dec 4.

8.

In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers.

Kikuchi T, Hassanein M, Amann JM, Liu Q, Slebos RJ, Rahman SM, Kaufman JM, Zhang X, Hoeksema MD, Harris BK, Li M, Shyr Y, Gonzalez AL, Zimmerman LJ, Liebler DC, Massion PP, Carbone DP.

Mol Cell Proteomics. 2012 Oct;11(10):916-32. Epub 2012 Jul 3.

9.

Long-term double-blind comparison of fenbufen with aspirin in the treatment of rheumatoid arthritis.

Roth SH, Cryan WS, Harris BK, Klipper AR, Kolodny LA, Rochmis PG, Schwartz HA, Virshup AM.

Pharmacology. 1982;25 Suppl 1:63-72. No abstract available.

PMID:
7111385
10.

Septal perforation with saddle nose deformity in rheumatoid arthritis.

Harris BK, Tello R.

Arthritis Rheum. 1979 Jan;22(1):101-2. No abstract available.

PMID:
758916
11.

Histocompatibility antigens and rheumatic diseases.

Harris BK.

Ariz Med. 1978 Apr;35(4):265-6. No abstract available.

PMID:
306811
12.

Myocardial infarction after a gold-induced nitritoid reaction.

Harris BK.

Arthritis Rheum. 1977 Nov-Dec;20(8):1561. No abstract available.

PMID:
921834
13.

Costs of monitoring chrysotherapy.

Harris BK, England DW, Ross HA, Roth SH.

Ariz Med. 1977 Apr;31(4):250-1. No abstract available.

PMID:
849168
14.

Letter: Rheumatoid disease.

Harris BK.

JAMA. 1976 May 17;235(20):2191. No abstract available.

PMID:
946842
15.

Longterm fenoprofen therapy in patients with rheumatoid arthritis.

Roth SH, Englund DW, Harris BK.

J Rheumatol. 1976;2:43-8.

PMID:
781230
16.

Hemarthrosis as the presenting manifestation of myeloproliferative disease.

Jackson WH, Harris BK, Ross HA.

Ariz Med. 1975 Apr;32(4):281-3. No abstract available.

PMID:
1119948
17.

Hemarthrosis as the presenting manifestation of myeloproliferative disease.

Harris BK, Ross HA.

Arthritis Rheum. 1974 Nov-Dec;17(6):969-70. No abstract available.

PMID:
4433355
18.

Quantitative study of doctor-patient communication in rheumatic diseases.

Harris BK, Chapman B, Roth SH, Englund DW.

Ariz Med. 1973 Apr;30(4):262-3. No abstract available.

PMID:
4540520
19.

Chronic synovitis as a manifestation of calcium crystal deposition disease.

Moskowitz RW, Harris BK, Schwartz A, Marshall G.

Arthritis Rheum. 1971 Jan-Feb;14(1):109-16. No abstract available.

PMID:
5100635

Supplemental Content

Loading ...
Support Center